Curriculum
Module 11 · 75 min
Disease Pathways & Drug Targets
From pathway knowledge to prescribing decisions and trial design.
CoreClinicalResearch
Topics
What this module covers
- 01How pathway maps shape NCCN guidelines
- 02Companion diagnostics and biomarker-driven therapy
- 03Pathway-level adverse-event prediction
- 04Combination therapy logic
Learning objectives
By the end of this module you will be able to
- L01Read a tumor molecular report and propose pathway-targeted options.
- L02Predict mechanism-based adverse events for three small-molecule classes.
- L03Distinguish vertical from horizontal pathway combinations.
Expected takeaways
What you should walk away believing
- →Most adverse events of targeted drugs are on-target, off-tissue.
- →Combination logic reduces resistance but compounds toxicity.
- →Biomarker testing precedes prescription in modern oncology.
Core summary
At the Core level
Once you know the pathways, the drugs almost design themselves. This module connects the dots between molecular reports, drug labels, and bedside reasoning.
Evidence-graded claims
Claims, scored A–F
A
Biomarker-driven trials outperform unselected ones
Schwaederle et al. meta-analysis.
E
Pathway combinations always improve survival
Many fail due to toxicity.
Quiz
Check your understanding
Q1. Companion diagnostic for trastuzumab?
Flashcards
Lock it in
1 / 2
Front
Vertical vs horizontal combination?
Click to flip